Watanabe, S.; Maeda, M.; Sugii, N.; Yamada, M.; Arakawa, Y.; Nakamura, K.; Hashimoto, K.; Ishikawa, E.
Trends in Efficacy Endpoints in Phase II Glioblastoma Trials: A Regulatory Science Analysis (FY2020–FY2022). Cancers 2025, 17, 855.
https://doi.org/10.3390/cancers17050855
AMA Style
Watanabe S, Maeda M, Sugii N, Yamada M, Arakawa Y, Nakamura K, Hashimoto K, Ishikawa E.
Trends in Efficacy Endpoints in Phase II Glioblastoma Trials: A Regulatory Science Analysis (FY2020–FY2022). Cancers. 2025; 17(5):855.
https://doi.org/10.3390/cancers17050855
Chicago/Turabian Style
Watanabe, Shinya, Makoto Maeda, Narushi Sugii, Masanobu Yamada, Yoshihiro Arakawa, Kimika Nakamura, Koichi Hashimoto, and Eiichi Ishikawa.
2025. "Trends in Efficacy Endpoints in Phase II Glioblastoma Trials: A Regulatory Science Analysis (FY2020–FY2022)" Cancers 17, no. 5: 855.
https://doi.org/10.3390/cancers17050855
APA Style
Watanabe, S., Maeda, M., Sugii, N., Yamada, M., Arakawa, Y., Nakamura, K., Hashimoto, K., & Ishikawa, E.
(2025). Trends in Efficacy Endpoints in Phase II Glioblastoma Trials: A Regulatory Science Analysis (FY2020–FY2022). Cancers, 17(5), 855.
https://doi.org/10.3390/cancers17050855